Temozolomide-induced hypermutation is associated with high-grade transformation, distant recurrence, and reduced survival after transformation in initially low-grade <i>IDH</i>-mutant diffuse gliomas.
Nancy Ann Oberheim Bush(University of California, San Francisco), J Costello(University of California, San Francisco), Joanna J. Phillips(University of California, San Francisco), David Solomon(University of California, San Francisco), Annette M. Molinaro(University of California, San Francisco), Yu Yao(Qinghai University), Javier Villanueva‐Meyer(Baylor College of Medicine), Jennifer Clarke(Cornell University), Stephanie Hilz(University of California, San Francisco), Anny Shai(University of California, San Francisco), Matthew Grimmer(Sequenom (United States)), Jennie Taylor(University of California, San Francisco), Daphne A. Haas‐Kogan(Brigham and Women's Hospital), Nicholas Butowski(University of California, San Francisco), Susan M. Chang(University of California, San Francisco), Serah Choi(University of Pittsburgh Medical Center), Mike McDermott(University of California, San Francisco), Tali Mazor(Dana-Farber Cancer Institute), Chibo Hong(Universidad Católica de Santa Fe), Mitchel S. Berger(University of California, San Francisco)
Cited by 4
Related Papers
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
|Nature|2008|7.8k
The NIH Roadmap Epigenomics Mapping Consortium
|Nature Biotechnology|2010|2k
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
|Nature|2012|2k
Molecular Determinants of the Response of Glioblastomas to EGFR Kinase Inhibitors
|New England Journal of Medicine|2005|1.4k
Aberrant CpG-island methylation has non-random and tumour-type–specific patterns
|Nature Genetics|2000|1.4k